Keith M Sullivan

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States
    Keith M Sullivan
    Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Biol Blood Marrow Transplant 16:S48-56. 2010
  2. ncbi request reprint Chronic graft-versus-host disease
    Mitchell E Horwitz
    Division of Cellular Therapy, Duke University Medical Center, 2400 Pratt Street DUMC 3961, Durham, NC 27710, USA
    Blood Rev 20:15-27. 2006
  3. doi request reprint Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning
    Junya Kanda
    Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Biol Blood Marrow Transplant 17:867-74. 2011
  4. doi request reprint "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma
    Cristina Gasparetto
    Department of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Biol Blood Marrow Transplant 16:70-7. 2010
  5. ncbi request reprint Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
  6. ncbi request reprint Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
    Jun ichi Nishimura
    PNH Research Committee, Duke University Medical Center, Durham, North Carolina 27710, USA
    Medicine (Baltimore) 83:193-207. 2004
  7. ncbi request reprint Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:569-75. 2004
  8. pmc Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:56-61. 2011
  9. ncbi request reprint Bone marrow transplantation for non-malignant disease
    Keith M Sullivan
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Hematol 76:169-70. 2002
  10. ncbi request reprint Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias
    Martin Goerner
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:47-56. 2002

Collaborators

Detail Information

Publications19

  1. pmc Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States
    Keith M Sullivan
    Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Biol Blood Marrow Transplant 16:S48-56. 2010
    ..These clinical trials will provide basic scientists with insight into immunoregulatory pathways and clinicians with a context to weigh the progress and evidence in this evolving treatment for autoimmune diseases...
  2. ncbi request reprint Chronic graft-versus-host disease
    Mitchell E Horwitz
    Division of Cellular Therapy, Duke University Medical Center, 2400 Pratt Street DUMC 3961, Durham, NC 27710, USA
    Blood Rev 20:15-27. 2006
    ..Topical therapy to affected areas is preferred for patients with mild disease. The 10-year survival of patients with mild chronic GVHD is approximately 80%, but is less than 5% for patients affected by severe chronic GVHD...
  3. doi request reprint Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning
    Junya Kanda
    Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Biol Blood Marrow Transplant 17:867-74. 2011
    ..This study supports the use of TBI 1350 cGy/Flu as an alternative to conventional myeloablative conditioning for dual UCB transplantation...
  4. doi request reprint "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma
    Cristina Gasparetto
    Department of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Biol Blood Marrow Transplant 16:70-7. 2010
    ..VMP did not negatively affect stem cell collection. Longer follow-up and prospective phase III trials are required to validate these initial observations...
  5. ncbi request reprint Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
    ..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype...
  6. ncbi request reprint Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan
    Jun ichi Nishimura
    PNH Research Committee, Duke University Medical Center, Durham, North Carolina 27710, USA
    Medicine (Baltimore) 83:193-207. 2004
    ..These data identify important differences between white and Asian patients with PNH. Identification of prognostic factors will help the design of prospective clinical trials for PNH...
  7. ncbi request reprint Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:569-75. 2004
    ..This result provides a basis for further exploring this potentially curative approach to selected patients who lack matched related or unrelated hematopoietic stem cell donors...
  8. pmc Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:56-61. 2011
    ..The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant...
  9. ncbi request reprint Bone marrow transplantation for non-malignant disease
    Keith M Sullivan
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Hematol 76:169-70. 2002
  10. ncbi request reprint Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias
    Martin Goerner
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:47-56. 2002
    ..Decisive improvements in therapy and survival will have to await both a better understanding of the immunological events underlying chronic GVHD and better infection prevention and control...
  11. pmc High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
    Peter A McSweeney
    University of Colorado Health Sciences Center, Denver 80262, USA
    Blood 100:1602-10. 2002
    ..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies...
  12. pmc High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:2364-72. 2003
    ..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...
  13. pmc High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 110:1388-96. 2007
    ..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial...
  14. ncbi request reprint Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia
    Robert Iannone
    Department of Pediatrics, Johns Hopkins Hospital and Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 9:519-28. 2003
    ....
  15. pmc Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Arthritis Rheum 54:1982-6. 2006
    ..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)...
  16. pmc Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 9:583-91. 2003
    ..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study...
  17. ncbi request reprint Cyclophosphamide in scleroderma lung disease
    Keith M Sullivan
    N Engl J Med 355:1173-4; author reply 1174. 2006
  18. ncbi request reprint Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis
    Jan Storek
    Clin Immunol 121:118-9. 2006
  19. ncbi request reprint High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward
    Daniel E Furst
    J Rheumatol 31:2331-5. 2004